[Nivolumab (melanoma, adjuvant, stage IIB or IIC) – Addendum to Project A23-94]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018011995
German
Original Title: Nivolumab (Melanom, adjuvant, Stadium IIB oder IIC) - Addendum zum Projekt A23-94
Details
Project Status: Completed
URL for project: https://www.iqwig.de/projekte/a24-23.html
Year Published: 2024
URL for published report: https://www.iqwig.de/download/a24-23_nivolumab_addendum-zum-projekt-a23-94_v1-0.pdf
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
DOI: https://doi.org/10.60584/A24-23
MeSH Terms
  • Melanoma
  • Adolescent
  • Adult
  • Nivolumab
  • Immune Checkpoint Inhibitors
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological
Keywords
  • Nivolumab
  • Melanoma
  • Adolescent
  • Adult
  • Benefit Assessment
  • NCT04099251
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.